Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model

Molecular Cancer Therapeutics

Volumn 12, Issue 12, 2013, Pages 2697-2708

  Gomes Giacoia, Evan ^a   Miyake, Makito ^a   Goodison, Steve ^a,b   Rosser, Charles J ^a,b  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b Nonagen Bioscience Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TIPLASININ;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; HELA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; UTERINE CERVIX CANCER; XENOGRAFT;

ANIMALS; ANOIKIS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENE KNOCKDOWN TECHNIQUES; HUMANS; INDOLEACETIC ACIDS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR BURDEN; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890471598     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0500     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 2011;186:2158-67.
3. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59:1009-18.
4. Calabró F, Sternberg CN. Metastatic bladder cancer: Anything new? Curr Opin Support Palliat Care 2012;6:304-9.
5. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, MooreMJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase 3 study. J Clin Oncol 2000;18:3068-77.
6. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23: 4602-8.
7. Sternberg CN, de Mulder PH, Schornagel JH, Théodore C, Fossa SD, van Oosterom AT, et al. Randomized phase III trial of high-doseintensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001;19:2638-46.
8. Urquidi V, Goodison S, Cai Y, Sun Y, Rosser CJ. A candidate molecular biomarker panel for the detection of bladder cancer. Cancer Epidemiol Biomarkers Prev 2012;21:2149-58.
9. Goodison S, Chang M, Dai Y, Urquidi V, Rosser CJ. A multi-analyte assay for the non- invasive detection of bladder cancer. PLoS ONE 2012;7:e47469.
10. Villadsen SB, Bramsen JB, Ostenfeld MS, Wiklund ED, Fristrup N, Gao S, et al. The miR- 143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Br J Cancer 2012;106:366-74.
11. Becker M, Szarvas T, Wittschier M, vomDorp F, Tötsch M, Schmid KW, et al. Prognostic impact of plasminogen activator inhibitor type 1 expression in bladder cancer. Cancer 2010;116:4502-12.
12. Pyke C, Kristensen P, Ralfkiaer E, Eriksen J, Danø K. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res 1991;51:4067-71.
13. Almholt K, Lund LR, Rygaard J, Nielsen BS, Danø K, Rømer J, et al. Reduced metastasis of transgenic mammary cancer in urokinasedeficient mice. Int J Cancer 2005;113:525-32.
14. Shapiro RL, Duquette JG, Roses DF, Nunes I, Harris MN, Kamino H, et al. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wildtype mice: Cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res 1996;56: 3597-604.
15. Sabapathy KT, Pepper MS, Kiefer F, Möhle-Steinlein U, Tacchini- Cottier F, Fetka I, et al. Polyoma middle T-induced vascular tumor formation: the role of the plasminogen activator/plasmin system. J Cell Biol 1997;137:953-63.
16. Praus M, Collen D, Gerard RD. Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis. Int J Cancer 2002;102:584-91.
17. Soff GA, Sanderowitz J, Gately S, Verrusio E, Weiss I, Brem S, et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 1995;96:2593-600.
18. Gorlatova NV, Cale JM, Elokdah H, Li D, Fan K, Warnock M, et al. Mechanism of nactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor. J Biol Chem 2007;282:9288-96.
19. Fang H, Placencio VR, DeClerck YA. Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. J Natl Cancer Inst 2012;104:1470-84.
20. Leik CE, Su EJ, Nambi P, Crandall DL, Lawrence DA. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost 2006;4:2710-5.
21. Miyake M, Goodison S, Giacoia EG, Rizwani W, Ross S, Rosser CJ. Influencing factors on the NMP-22 urine assay: An experimental model. BMC Urol 2012;12:23-27.
22. Anai S, Goodison S, Shiverick K, Hirao Y, Brown BD, Rosser CJ. Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Mol Cancer Ther 2007;6:101-11.
23. Badiga AV, Chetty C, Kesanakurti D, Are D, Gujrati M, Klopfenstein JD, et al.MMP- 2siRNA inhibits radiation-enhanced invasiveness in glioma cells. PLoS ONE 2011;6:e20614.
24. Pfaffl MW. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res 2001;29:e45.
25. Anai S, Sakamoto N, Sakai Y, Tanaka M, Porvasnik S, Urbanek C, et al. Dual targeting of Bcl-2 and VEGF: A potential strategy to improve therapy for prostate cancer. Urol Oncol 2011;29:421-9.
26. Rømer MU, Kirkebjerg Due A, Knud Larsen J, Hofland KF, Christensen IJ, Buhl-Jensen P, et al. Indication of a role of plasminogen activator inhibitor type 1 in protecting murine fibrosarcoma cells against apoptosis. Thromb Haemost 2005;94:859-66.
27. Buchholz M, Biebl A, Neesse A, Wagner M, Iwamura T, Leder G, et al. SERPINE2 (protease nexin 1) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo. Cancer Res 2003;63: 4945-51.
28. Al-Fakhri N, Chavakis T, Schmidt-Wöll T, Huang B, Cherian SM, Bobryshev YV, et al. Induction of apoptosis in vascular cells by plasminogen activator inhibitor-1 and high molecular weight kininogen correlates with their anti-adhesive properties. J Biol Chem 2003;384: 423-35.
29. Chen SC, Henry DO, Reczek PR, Wong MK. Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis. Mol Cancer Ther 2008;7:1227-36.
30. Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, Selman SH, Jankun J. Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells. Oncol Rep 2004;12:1155-62.
31. Brooks TD, Wang SW, Br€unner N, Charlton PA. XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro. Anticancer Drugs 2004;15:37-44.
32. Wiman B, Collen D. Purification and characterization of human antiplasmin, the fast- acting plasmin inhibitor in plasma. Eur J Biochem 1977;78:19-26.
33. Stefansson S, Haudenschild CC, Lawrence DA. Beyond fibrinolysis: the role of plasminogen activator inhibitor-1 and vitronectin in vascular wound healing. Trends Cardiovasc Med 1998;8:175-80.
34. Wilkins-Port CE, Ye Q, Mazurkiewicz JE, Higgins PJ. TGF-beta1 + EGF-initiated invasive potential in transformed human keratinocytes is coupled to a plasmin/MMP-10/MMP-1- dependent collagen remodeling axis: role for PAI-1. Cancer Res 2009;69: 4081-91.
35. Hennan JK, Elokdah H, Leal M, Ji A, Friedrichs GS, Morgan GA, et al. Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1Hindol- 3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor- 1 inhibitor, in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther 2005;314:710-6.
36. Kunz C, Pebler S, Otte J, von der Ahe D. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res 1995;23:3710-7.
37. Cooper MJ, Haluschak JJ, Johnson D, Schwartz S, Morrison LJ, Lippa M, et al. p53 mutations in bladder carcinoma cell lines. Oncol Res 1994;6:569-79.
38. Mu XC, Staiano-Coico L, Higgins PJ. Increased transcription and modified growth state-dependent expression of the plasminogen activator inhibitor type-1 gene characterize the senescent phenotype in human diploid fibroblasts. J Cell Physiol 1998;174:90-8.
39. Ma D, Gerard RD, Li XY, Alizadeh H, Niederkorn JY. Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. Blood 1997;90:2738-46.
40. Jankun J, Keck RW, Skrzypczak-Jankun E, Swiercz R. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res 1997;57:559-63.
41. McMahon GA, Petitclerc E, Stefansson S, Smith E,Wong MK, Westrick RJ, et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 2001;276:33964-8.
42. Bajou K, Maillard C, Jost M, Lijnen RH, Gils A, Declerck P, et al. Hostderived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 2004;23:6986-90.
43. Kwaan HC, Wang J, Svoboda K, Declerck PJ. Plasminogen activator inhibitor 1may promote tumour growth through inhibition of apoptosis. Br J Cancer 2000;82:1702-8.
44. Lademann U, Rømer MU, Jensen PB, Hofland KF, Larsen L, Christensen IJ, et al. alignant transformation of wild-type but not plasminogen activator inhibitor-1 gene- deficient fibroblasts decreases cellular sensitivity to chemotherapy-mediated apoptosis. Eur J Cancer 2005;41:1095-100.
45. Ramachandra M, Atencio I, Rahman A, Vaillancourt M, Zou A, AvanziniJ, et al. estoration of transforming growth factor Beta signaling by functional expression of smad4 induces anoikis. Cancer Res 2002;62: 6045-51.
46. Schneider DJ, Chen Y, Sobel BE. The effect of plasminogen activator inhibitor type 1 on apoptosis. Thromb Haemost 2008;100:1037-40.
47. Bajou K, Peng H, Laug WE, Maillard C, Noel A, Foidart JM, et al. Plasminogen activator inhibitor-1 protects endothelial cells from FasLmediated apoptosis. Cancer Cell 2008;14:324-34.
48. McGarvey TW, Kariko K, Barnathan ES, Thomas J, Malkowicz SB. The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma. Int J Oncol 1998;12:175-80.
49. Kobayashi H, Fujishiro S, Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 1994;54:6539-48.
50. Tee YT, Wang PH, Tsai HT, Lin LY, Lin HT, Yang SF, et al. Genetic polymorphism of urokinase-type plasminogen activator is interacting with plasminogen activator inhibitor-1 to raise risk of cervical neoplasia. J Surg Oncol 2012;106:204-8.